DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Application Status
This action is written in response to applicant’s correspondence received 6 July 2026. Claims 84-85, 87-88, 91-105, and 113-114 are currently pending. Accordingly, claims 84-85, 87-88, 91-105, and 113-114 are examined herein. The restriction requirement mailed 4 October 2024 is still deemed proper. Applicant's elected Group I, claims 84-114, alongside the species of 67 and 28 without traverse in the reply filed 4 December 2024.
Any rejection or objection not reiterated herein has been overcome by amendment.
Applicant' s amendments have been thoroughly reviewed, but are not persuasive to place the
claims in condition for allowance for the reasons that follow.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 84-85, 87-88, 91-94, and 113-114 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for a method of modulating expression of a target MeCP2 target peptide sequence by a cell having an endogenous MeCP2 pre-mRNA, does not reasonably provide enablement for the modulation of any target peptide sequence by a cell having any endogenous pre-mRNA in order to produce a fully functional first protein and at least a partially functional second protein. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.
Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described by the court in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). Wands states, on page 1404:
Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in Ex part Forman. They include (1 the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of these in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.
Regarding claims 84 and 114, the claims require increasing the expression of a target peptide sequence in a cell through the splicing of a pre-mRNA sequence encoding the target peptide sequence that comprises a first start codon, a second start codon, and a PTC located between the first and second start codons, the method comprising contacting the cell with an ASO that is 12-50 nucleobases in length, wherein contacting the cell with the ASO results in an increased splicing of a region comprising the PTC and second start codon such that the expression of an mRNA that encodes a first protein comprising the target peptide sequence and devoid of both the PTC and second start codon is increased (see Claim 84). The claim requires that the first protein has a higher translation efficiency than a second protein that is otherwise identical to the first protein but comprises the region comprising the PTC and second start codon (see Claim 84). The claim requires that the first protein is translated starting from the first start codon while the second protein is translated starting from the second start codon (see Claim 84). The claim also requires that the first protein is a fully functional protein and the second protein is at least a partially functional protein (see Claim 84).
The claims are not enabled for the modulation of any target peptide sequence within any endogenous pre-mRNA through the use of any ASO in order to produce a first fully functional protein and a second at least partially functional protein as claimed.
Nature of the Invention
Regarding claims 84 and 114, the nature of the invention is a method of utilizing an antisense oligomer to modulate the splicing of any pre-mRNA comprising in order to generate either a first fully functional protein or an at least partially functional second protein.
The claim concerns a biologically complex relationship between the claimed antisense oligomer and the resulting splicing of the claimed pre-mRNA molecule, wherein neither the antisense oligomer, pre-mRNA molecule, or resultant proteins are limited to a specific gene.
Breadth of the Claims
Regarding the claims, it is noted that the claimed method is not limited to a particular pre-mRNA, a particular target peptide sequence, a particular first or second protein, a particular antisense oligomer sequence, or a particular cell type.
Therefore, the clams are drawn towards the modulation of any endogenous pre-mRNA that comprises the claimed start codons and PTC, wherein the claimed antisense oligomer can be of any structure so long as it modulates the splicing of the PTC and second start codon.
State of the Art/Predictability of the Art
It is well established in the prior art that there are antisense molecules that can generate alternative splicing products. However, the prior art further provides evidence that the structure of the antisense molecules that interact with the pre-mRNA must be of a specific structure in order to achieve the claimed result.
Collin is drawn towards an invention concerned with novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis (Abstract). Collin teaches that the expression of a target CEP290 peptide that is encoded by an endogenous CEP290 pre-mRNA can be modulated through the use of an antisense oligonucleotide comprising a specific structure ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). Collin teaches that the antisense oligonucleotide can be about 12-30 nucleotides in length ([0024]). Collin teaches that mutant endogenous CEP290 pre-mRNA comprises, 5’ to 3’, a first start codon present in exon 26, an aberrant exon (i.e., encoded by intron 26) comprising a premature start codon that is expressed in the mutated non-spliced CEP290 mRNA such that an incorrect CEP290 protein that expresses the aberrant exon is generated, followed by exon 27 ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). Collin teaches that the antisense oligonucleotide can bind to a targeted region of intron 26 in the mutant CEP290 pre-mRNA such that the splicing of the aberrant exon is modulated and a first protein comprising only exons 26-27 is produced and a correct CEP290 protein is encoded ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). However, Collin further teaches that in order to design the antisense oligonucleotides the entire aberrant exon needed to be sequenced and multiple different antisense molecule targeted to different regions of the exon comprising exonic splice enhancer binding motifs tested in order to determine their ability to successfully skip the exon ([0129]).
However, Collins does not teach or suggest that the alternative splice products produced two of the claimed proteins (i.e., a first functional protein and a second at least partially functional protein) are generated from the two claimed start codons wherein the claimed expressional relationship between the two products is maintained (see Claims 84 and 114). Additionally, Collins does not teach or suggest that it was predictable that any antisense molecule targeted to the CEP290 pre-mRNA could achieve the claimed splicing products because Collins teaches that the antisense molecules needed to have a specific structure and target specific motifs in the aberrant exon in order to induce the splicing.
Therefore, the closest prior art concerned with the claimed method demonstrates that the structure of the antisense molecules that interact with the pre-mRNA must be of a specific structure in order to achieve the generation of alternative splicing products.
Amount of Direction Provided by the Inventor/Existence of Working Examples
Regarding the amount of direction provided by the instant specification, the instant specification discloses a single embodiment of how the claimed method may be performed through the modulation of MeCP2 pre-mRNA (see Examples 1 and 4; see FIGs. 1-2). The instant specification teaches that MeCP2 can be alternatively spliced into two different isoforms, MeCP2α (i.e., wherein exon 2 is spliced out from the mRNA and translation begins at a start codon present in exon 1) and MeCP2β (i.e., wherein exon 2 is not spliced out and translation begins at a start codon present in exon 2) (see FIG. 1A). The instant specification teaches that when there is a premature stop codon present in exon 2, the resultant mRNA is “Nonproductive” (i.e., interpreted as no protein being produced from the mRNA) (see FIG. 1A). The instant specification teaches the use of an antisense oligomer that can splice out exon 2 and result in the expression of only MeCP2α irrespective of the presence of a PTC (see FIG. 2). Additionally, the instant specification teaches the use of an antisense oligomer, ASO1, that targets MeCP2 but had no effect on exon 2 splicing and an antisense oligomer, ASO52, that targets MeCP2 but results in exon 2 inclusion ([00365]; see Example 4). The instant specification also identifies exemplary genes and exons containing PTC and an alternative start codon (pg. 45-66; see Table 1). It is noted that the exemplary genes and exons disclosed in the instant specification must comprise a specific structure and corresponding genomic coordinates (pg. 45-66; see Table 1).
However, the claim requires substantially more than the identification of an exon that comprises a PTC and an alternative start codon. The claim requires that an antisense oligomer, not limited by sequence except for the targeting of the claimed pre-mRNA, can actually produce the claimed splice product and that the claimed first and second proteins that have the claimed translation efficiencies when compared to one another from a pre-mRNA not limited by sequence. Although MPEP 2164 teaches that a specification need not describe working examples of every possible embodiment of the claim, the limited examples present in the instant specification are relevant to the lack of enablement because of the teachings present in the instant specification demonstrating sequence dependence of the antisense oligomers in order to achieve the claimed result alongside very limited guidance for the utilization of the claimed method to alternatively splice pre-mRNA other than the MeCP2 pre-mRNA. Additionally, the instant specification provides evidence that there exist antisense oligomers that can target pre-mRNA that fall within the claimed method and no splicing products are produced. Because the instant specification provides no evidence that the pre-mRNA not limited by sequence and antisense oligomers not limited by sequence, other than the requirement that they are complementary to the pre-mRNA, can be utilized to produce the claimed first and second proteins that have the claimed functional relationship, the instant specification does not provide any particular direction or guidance which resolves the known unpredictability in the art associated with the utilization of the claimed antisense oligomers to produce the alternative splicing products of target pre-mRNA.
Relative Skill of the Ordinary Artisan/Amount of Experimentation Required
With regard to the claims, the skill of those in the relative art is high, but still, given the
state and unpredictability of the art, undue experimentation would be required to determine if a particular antisense oligomer could be utilized in the method to achieve the claimed alternative splicing product. For example, to even select a single suitable pre-mRNA molecule, confirmation of possible alternative splicing products would need to be confirmed following extensive sequence analysis and identification of the relationship between the products’ expression levels. To generate a single antisense oligomer, extensive sequence analysis would need to be performed and at least an antisense oligomer walk performed across the claimed pre-mRNA region performed in order to determine if the expression of the resulting claimed splicing products were modulated. Following contacting with the generated antisense oligomer, protein expression assays would need to be performed and the analysis of the functional level of the claimed first and second proteins determined. All of these method steps would need to be performed for each individual species of claimed pre-mRNA. Thus, the amount of experimentation required is enormous. Therefore, performing the method as claimed cannot be predictably accomplished, as presently claimed.
Thus, the claims are not enabled commensurate in scope with the claimed invention.
Regarding claims 85, 87-88, 91-94, and 113, as the claims are ultimately dependent on claim 84 and do not rectify the 35 USC 112(a) enablement rejection above, the claims are also rejected under 35 USC 112(a).
Claims 84-85, 87-88, 91-94, 97, 99, 102, and 113-114 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Regarding claims 84 and 114, the claims require increasing the expression of a target peptide sequence in a cell through the splicing of a pre-mRNA sequence encoding the target peptide sequence that comprises a first start codon, a second start codon, and a PTC located between the first and second start codons, the method comprising contacting the cell with an ASO that is 12-50 nucleobases in length, wherein contacting the cell with the ASO results in an increased splicing of a region comprising the PTC and second start codon such that the expression of an mRNA that encodes a first protein comprising the target peptide sequence and devoid of both the PTC and second start codon is increased (see Claim 84). The claim requires that the first protein has a higher translation efficiency than a second protein that is otherwise identical to the first protein but comprises the region comprising the PTC and second start codon (see Claim 84). The claim requires that the first protein is translated starting from the first start codon while the second protein is translated starting from the second start codon (see Claim 84). The claim also requires that the first protein is a fully functional protein and the second protein is at least a partially functional protein (see Claim 84).
Accordingly, the claims are interpreted as claiming a genus of antisense oligomers that have the function of being able to generate the first claimed protein that is fully functional and has a higher translation efficiency than the second claimed protein. Additionally, the claims are interpreted as encompassing a second protein that is at least partially functional as defined by the instant specification ([0069]). The instant specification teaches that the term “partially functional” refers to a functional definition wherein the term is defined as any amount of activity or function of the protein that is less than the amount of activity or function that is necessary to eliminate or prevent any one or more symptoms of a disease or condition ([0069]).
The instant specification does not provide support for the use of a genus of antisense oligomers that can perform the claimed function, nor the genus of claimed second proteins that are at least partially functional, and the closest prior art provides evidence that the antisense molecules that interact with the pre-mRNA must be of a specific structure in order to achieve the claimed result.
The MPEP lists factors that can be used to determine if sufficient evidence of possession has been furnished in the disclosure of the application. These include "level of skill and knowledge in the art, partial structure, physical and/or chemical properties, functional characteristics alone or coupled with a known or disclosed correlation between structure and function, and the method of making the claimed invention. Disclosure of any combination of such identifying characteristics that distinguish the claimed invention from other materials and would leave one of skill in the art to the conclusion that the applicant was in possession of the claimed species is sufficient." MPEP 2163. A claimed genus may be satisfied through sufficient descriptions of a representative number of species or disclosure of relevant, identifying characteristics such as functional characteristics coupled with known or disclosed correlation between function and structure. MPEP 2163(3)a(II). The number of species that describe the genus must be adequate to describe the entire genus; if there is substantial variability, a large number of species must be described.
The analysis for adequate written description considers (a) actual reduction to practice, (b) disclosure of drawings or structural chemical formulas, (c) sufficient relevant identifying characteristics in the way of complete/partial structure or physical and/or chemical properties or functional characteristics when coupled with known or disclosed correlation with structure, and (d) representative number of samples.
As the claims currently recite, as described above, the claims are broadly drawn towards a method of utilizing an antisense oligomer to modulate the splicing of any pre-mRNA comprising in order to generate either a first fully functional protein or an at least partially functional second protein.
While claiming a genus of structures (i.e., antisense oligomers and second proteins) by a function (i.e., the ability to generate the claimed proteins wherein the proteins are at least partially functional) is not prohibited, there must be a sufficient structure-function relationship described in the specification such that the claimed genus was represented by a representative number of species or the teachings of the specification, or, the prior art can be used to support a well-known structure-function relationship.
In the instant case, the instant specification does not provide support that the total genus of claimed antisense oligomers were able to generate the claimed proteins and does not provide evidence for a genus of partially functional second proteins as claimed. Further, the both the prior art and the instant specification demonstrate that the antisense molecules that interact with the pre-mRNA must be of a specific structure in order to achieve the claimed result and that utilizing a genus of antisense oligomers to perform the claimed function is unpredictable.
Working Examples
With regard to working examples, the specification provides little evidence on the possession of a sufficient number of species which are encompassed by the entirety of the claimed genus.
MPEP 2163 teaches that “for some arts, there is an inverse correlation between the level of skill and knowledge in the art and the specificity of disclosure necessary to satisfy the written description requirement. Information which is well known in the art need not be described in detail in the specification. See, e.g., Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1379-80, 231 USPQ 81, 90 (Fed. Cir. 1986). However, sufficient information must be provided to show that the inventor had possession of the invention as claimed [emphasis added].”
In the instant case, regarding the claimed genus of antisense oligomer, the instant specification discloses a single embodiment of how the claimed method may be performed through the modulation of MeCP2 pre-mRNA (see Examples 1 and 4; see FIGs. 1-2). The instant specification teaches that MeCP2 can be alternatively spliced into two different isoforms, MeCP2α (i.e., wherein exon 2 is spliced out from the mRNA and translation begins at a start codon present in exon 1) and MeCP2β (i.e., wherein exon 2 is not spliced out and translation begins at a start codon present in exon 2) (see FIG. 1A). The instant specification teaches the use of an antisense oligomer that can splice out exon 2 and result in the expression of only MeCP2α irrespective of the presence of a PTC (see FIG. 2). However, the instant specification teaches the use of an antisense oligomer, ASO1, that targets MeCP2 but had no effect on exon 2 splicing and an antisense oligomer, ASO52, that targets MeCP2 but results in exon 2 inclusion ([00365]; see Example 4). Thus, the instant specification teaches the use of antisense oligomers that fall within the claimed genus but do not perform the claimed function.
Regarding the claimed partially functional protein, the instant specification teaches that when there is a premature stop codon present in exon 2, the resultant mRNA is “Nonproductive” (see FIG. 1A). In addition, FIG. 2 provides evidence that translation begins at exon 2 in the MeCP2α and MeCP2β isoforms, but not the isoform comprising the PTC (see FIG. 2). The instant specification does teach that a partially functional MECP2 p.A140V variant was generated and expressed in mice ([000372]; see Example 7); however, because the instant specification does not provide a definition for what it means for an mRNA to be “Nonproductive”, alongside the lack of an initiation of translation in FIG. 2 in the mRNA comprising the PTC, the phrase is interpreted as encompassing mRNA that does not produce a functional protein. Thus, the instant specification does not provide support for the genus of claimed second proteins being at least partially functional. Additionally, it is not described in the specification how much of a partially functional protein is required to prevent which symptoms of which diseases.
Thus, the instant specification does not provide written description for the entirety of the claimed antisense oligomers that can perform the claimed function or structures of second proteins that are at least partially functional as required by the claim.
Prior Art
Regarding the state of the prior art, it is well established in the prior art that there are antisense molecules that can generate alternative splicing products. However, the prior art further provides evidence that the structure of the antisense molecules that interact with the pre-mRNA must be of a specific structure in order to achieve the claimed result.
Collin is drawn towards an invention concerned with novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis (Abstract). Collin teaches that the expression of a target CEP290 peptide that is encoded by an endogenous CEP290 pre-mRNA can be modulated through the use of an antisense oligonucleotide comprising a specific structure ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). Collin teaches that the antisense oligonucleotide can be about 12-30 nucleotides in length ([0024]). Collin teaches that mutant endogenous CEP290 pre-mRNA comprises, 5’ to 3’, a first start codon present in exon 26, an aberrant exon (i.e., encoded by intron 26) comprising a premature start codon that is expressed in the mutated non-spliced CEP290 mRNA (i.e., the aberrant exon comprises a second start codon) such that an incorrect CEP290 protein that expresses the aberrant exon is generated, followed by exon 27 ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). Collin teaches that the antisense oligonucleotide can bind to a targeted region of intron 26 in the mutant CEP290 pre-mRNA such that the splicing of the aberrant exon is modulated and a first protein comprising only exons 26-27 is produced and a correct CEP290 protein is encoded ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). However, Collin further teaches that in order to design the antisense oligonucleotides the entire aberrant exon needed to be sequenced and multiple different antisense molecule targeted to different regions of the exon comprising exonic splice enhancer binding motifs tested in order to determine their ability to successfully skip the exon ([0129]). Additionally, the prior art does not teach that the utilization of a partially functional protein as claimed is well understood in the art nor could be generated through the use of the antisense oligonucleotides to treat Leber congenital amaurosis.
Therefore, the closest prior art concerned with the claimed method demonstrates that the structure of the antisense molecules that interact with the pre-mRNA must be of a specific structure in order to achieve the generation of alternative splicing products. Additionally, the prior art provides evidence that the generation of a second partially functional protein as claimed is not well understood nor predictable.
Conclusion
The specification does not identify a representative number of species of the broadly claimed antisense oligomers or structures of second proteins comprising a partially functional structure as defined by the instant specification. Further, the prior art shows that prior to the effective filing date of the claimed invention that designing determining the ability for a specific antisense molecule to achieve an intended splice product is sequence specific.
Therefore, a person of ordinary skill in the art would not have concluded that Applicant was in possession of the invention as claimed. Thus, claim 84 is rejected under 35 U.S.C. 112(a).
Regarding claims 85, 87-88, 91-94, 97, 99, 102, and 113, as the claims are ultimately dependent on claim 84 and do not rectify the 35 USC 112(a) rejection above, the claims are also rejected under 35 USC 112(a).
Allowable Subject Matter
Claims 95-96, 98-101, and 103-105 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Closest Prior Art
Regarding claims 84 and 114, the closest prior art is the combination of Collin (PG Pub No. US 2018/0228829) and Mnatzakanian (Nature genetics 36.4 (2004): 339-341).
Regarding claims 84 and 114, Collin is drawn towards an invention concerned with novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis (Abstract). Collin teaches that the expression of a target CEP290 peptide that is encoded by an endogenous CEP290 pre-mRNA can be modulated through the use of an antisense oligonucleotide comprising a specific structure ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). Collin teaches that the antisense oligonucleotide can be about 12-30 nucleotides in length ([0024]). Collin teaches that mutant endogenous CEP290 pre-mRNA comprises, 5’ to 3’, a first start codon present in exon 26, an aberrant exon (i.e., encoded by intron 26) comprising a premature start codon that is expressed in the mutated non-spliced CEP290 mRNA such that an incorrect CEP290 protein that expresses the aberrant exon is generated, followed by exon 27 ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). Collin teaches that the antisense oligonucleotide can bind to a targeted region of intron 26 in the mutant CEP290 pre-mRNA such that the splicing of the aberrant exon is modulated and a first protein comprising only exons 26-27 is produced and a correct CEP290 protein is encoded ([0002], [0097]-[0099], [0202]; see FIGs. 1A-1C). Collin further teaches that in order to design the antisense oligonucleotides the entire aberrant exon needed to be sequenced and multiple different antisense molecule targeted to different regions of the exon tested in order to determine their ability to successfully skip the exon ([0129]).
Thus, Collin provides evidence that splicing an aberrant exon through the use of an antisense oligomer was a known method of generating alternative splicing products.
Additionally, Mnatzakanian is drawn to a study concerned with new protein isoforms relevant to Rett syndrome (Abstract). Mnatzakanian teaches that Rett syndrome is caused by mutations in the MECP2 gene (Abstract). Mnatzakanian teaches that an unmodified MECP2 gene is comprised of exons 1-4 and encodes a MECP2A splice variant (i.e., a second processed mRNA) that comprises a start codon within exon 2 that results Rett syndrome when expressed in cells (i.e., MECP2A is encoded by exons 2-4 of the MECP2 gene) (pg. 340; see Figure 1A). Mnatzakanian teaches that exon 2 has a number of in-frame stop codons upstream of an out-of-frame ATG start codon (i.e., exon 2 comprises premature stop codons located between a first start codon of exon 1 and a second start codon) (pg. 339). Mnatzakanian teaches that exon 2 can be spliced out in order to generate an MECP2B splice variant (i.e., a first processed mRNA generated from exons 1, 3, and 4 of the MECP2 gene) that had ten times higher expression levels than MECP2A splice variants in adult human brains (pg. 339). Mnatzakanian teaches that MECP2A is translated from the second start codon while MECP2B is translated from the first start codon (pg. 340; see Figure 1A).
However, neither Collin nor Mnatzakanian teaches or suggests that the level of the first processed mRNA (i.e., MECP2B) should be increased via the splicing of the exon comprising the PTC and second start codon as compared to a second mRNA encoding the second protein (i.e., MECP2A) (Claims 84 and 114).
While Mnatzakanian discloses that expression levels vary in the tissues and that certain mutations can result in absent or truncated MeCP2B protein, Mnatzakanian teaches that both isoforms exist and have their own important functions across various tissue types, while the differences in the level of expression of one isoform or another is the aspect correlated with the disease state and not caused by the expression of one isoform. Thus, a person of ordinary skill in the art would not have been motivated to, nor would have expected that, increasing the expression of a particular MeCP2 isoform had a therapeutic benefit as demonstrated by Applicant (Instant specification; [00372]-[0000375]). Accordingly, the claims are both novel and non-obvious in view of the closest prior art.
Response to Arguments
Applicant’s arguments with respect to the newly amended claim(s) 84-85, 87-88, 91-105, and 113-114 and the previously pending 35 USC 102 and 103 rejections of record have been considered and have been considered persuasive. Accordingly, the previously pending 35 USC 102 and 103 rejections of record have been withdrawn.
However, the newly amended claim limitations present in the claims necessitated the newly filed 35 USC 112(a) rejections of record above. Thus, claims 84-85, 87-88, 91-94, 97, 99, 102, and 113-114 are rejected.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE T REGA whose telephone number is (571)272-2073. The examiner can normally be reached Mon-Fri, 9AM-5PM (EDT/EST).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Neil Hammell can be reached at 571-270-5919. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KYLE T REGA/Examiner, Art Unit 1636
/NEIL P HAMMELL/Supervisory Patent Examiner, Art Unit 1636